Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label Study to Assess the Absorption, Distribution, Metabolism, and Excretion (ADME) of AZD1390 After a Single Oral Dose of [14C]-AZD1390 in Participants With Advanced Solid Malignancies

NCT07643870 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07643870
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07643870 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label Study to Assess the Absorption, Distribution, Metabolism, and Excretion (ADME) of AZD1390 After a Single Oral Dose of [14C]-AZD1390 in Participants With Advanced Solid Malignancies
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Not yet recruiting
Start date
June 30, 2026
Completion date
April 12, 2028
Enrollment
8 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid malignancies